July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Effect of IOP Reduction by Latanoprost on Corneal Biomechanical Properties in Glaucomatous Eyes Using Ultrasound Surface Wave Elastography
Author Affiliations & Notes
  • Arash Kazemi
    Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota, United States
  • Boran Zhou
    Department of Radiology, Mayo Clinic, Rochester, Minnesota, United States
  • Xiaoming Zhang
    Department of Radiology, Mayo Clinic, Rochester, Minnesota, United States
  • Arthur J Sit
    Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota, United States
  • Footnotes
    Commercial Relationships   Arash Kazemi, None; Boran Zhou, None; Xiaoming Zhang, Mayo Clinic (P); Arthur Sit, None
  • Footnotes
    Support  1- Research to Prevent Blindness, 2- Mayo Foundation for Medical Education and Research, 3- NIH R21 Grant (EY026095, Co-PI AJS, XZ) from the National Eye Institute
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 6196. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Arash Kazemi, Boran Zhou, Xiaoming Zhang, Arthur J Sit; Effect of IOP Reduction by Latanoprost on Corneal Biomechanical Properties in Glaucomatous Eyes Using Ultrasound Surface Wave Elastography. Invest. Ophthalmol. Vis. Sci. 2019;60(9):6196.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Biomechanical properties of the eye are important for understanding the risk of glaucoma, but the effect of IOP reduction is poorly understood. In this study, we investigated the effect of latanoprost treatment on wave speed propagation as a measure of corneal elasticity in glaucomatous eyes.

Methods : Twenty-four eyes from 12 subjects with POAG or NTG (62 ± 11 years, mean±SD) were included. Measurements were performed at two time points: 1. Un-medicated (prior to initiating therapy or after a 6 week washout); and 2. Medicated (after ≥6 weeks of latanoprost). IOP was measured by pneumatonometry. The ocular rigidity coefficient (OR) was calculated from IOP measured in the supine position with and without a 10 g weight added to the pneumatonometer. Axial length (AL) was measured by A-scan ultrasonography. Central corneal thickness (CCT) was measured by using Scheimpflug imaging. Corneal wave speed was determined by surface wave elastography (SWE). With this technique, a handheld shaker was placed on the closed eyelid to generate a small, 0.1 s harmonic vibration at 100 Hz. Wave propagation in the cornea was measured by SWE, and wave speed was determined from the change in phase with distance. Medicated and un-medicated measurements were compared by using generalized estimating equation models. Correlations between wave speed and other parameters were determined by regression analysis.

Results : IOP decreased with latanoprost treatment, from 24.2 ± 6.3 mmHg to 17.2 ± 2.3 mmHg (P<0.001). There were no significant changes in corneal wave speed (2.18 ± 0.29 m/s vs 2.21 ± 0.25 m/s, P=0.58), OR (0.0212 ± 0.006 μL-1 vs 0.0215 ± 0.005 μL-1, P=0.77), CCT (554.9 ± 34.8 μm vs 552.3 ± 33.5 μm, P=0.26), and AL (24.82 ± 1.5 mm vs 24.77 ± 1.5 mm, P=0.08) with latanoprost. Corneal wave speed was moderately correlated with un-medicated IOP (r=0.55, P<0.001) but not with medicated IOP, OR, CCT, or AL (P>0.05).

Conclusions : Corneal elasticity, as indicated by wave speed, and ocular rigidity do not change after IOP reduction with latanoprost in glaucomatous eyes. Corneal wave speed and IOP were correlated in un-medicated eyes, consistent with previous research. The lack of a correlation in medicated eyes may be due to a narrower IOP range. Further studies are required to determine the effect of IOP reduction on sclera, and the effect of other glaucoma medications.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×